These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 36569912)

  • 1. Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis.
    McCombe PA; Hardy TA; Nona RJ; Greer JM
    Front Immunol; 2022; 13():1038411. PubMed ID: 36569912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Press R; Pashenkov M; Jin JP; Link H
    J Clin Immunol; 2003 Jul; 23(4):259-67. PubMed ID: 12959218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions.
    Blum S; McCombe PA
    J Peripher Nerv Syst; 2014 Jun; 19(2):88-103. PubMed ID: 25039604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siponimod ameliorates experimental autoimmune neuritis.
    Uchi T; Konno S; Kihara H; Fujioka T
    J Neuroinflammation; 2023 Feb; 20(1):35. PubMed ID: 36788526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Csurhes PA; Sullivan AA; Green K; Pender MP; McCombe PA
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1431-9. PubMed ID: 16170091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification.
    Eldar AH; Chapman J
    Autoimmun Rev; 2014; 13(4-5):525-30. PubMed ID: 24434363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of HLA associations in male and female patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
    McCombe PA; Csurhes PA; Greer JM
    J Neuroimmunol; 2006 Nov; 180(1-2):172-7. PubMed ID: 16935351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of vasoactive intestinal peptide in the rat model of experimental autoimmune neuritis and the implications for treatment of acute inflammatory demyelinating polyradiculoneuropathy or Guillain-Barré syndrome.
    Jiao H; Ren H
    Drug Des Devel Ther; 2018; 12():3817-3824. PubMed ID: 30464413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome.
    Zhu J; Mix E; Link H
    J Neuroimmunol; 1998 Apr; 84(1):40-52. PubMed ID: 9600707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.
    Querol L; Lleixà C
    Neurotherapeutics; 2021 Oct; 18(4):2222-2235. PubMed ID: 34549385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.
    Zhang HL; Zheng XY; Zhu J
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):443-53. PubMed ID: 23791985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy.
    Moalem-Taylor G; Allbutt HN; Iordanova MD; Tracey DJ
    Brain Behav Immun; 2007 Jul; 21(5):699-710. PubMed ID: 17005365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models of autoimmune neuropathy.
    Soliven B
    ILAR J; 2014; 54(3):282-90. PubMed ID: 24615441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome.
    Yuan F; Yosef N; Lakshmana Reddy C; Huang A; Chiang SC; Tithi HR; Ubogu EE
    PLoS One; 2014; 9(3):e90463. PubMed ID: 24632828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunopathology and treatments of Guillain-Barré syndrome and of chronic inflammatory demyelinating polyneuropathy].
    Radziwill AJ; Kuntzer T; Steck AJ
    Rev Neurol (Paris); 2002 Mar; 158(3):301-10. PubMed ID: 11976589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular immunity in inflammatory autoimmune neuropathies.
    Mäurer M; Toyka KV; Gold R
    Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S7-15. PubMed ID: 12690655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
    Ruts L; Drenthen J; Jacobs BC; van Doorn PA;
    Neurology; 2010 May; 74(21):1680-6. PubMed ID: 20427754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Press R; Nennesmo I; Kouwenhoven M; Huang YM; Link H; Pashenkov M
    J Neuroimmunol; 2005 Feb; 159(1-2):165-76. PubMed ID: 15652416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis.
    Shen D; Chu F; Lang Y; Geng Y; Zheng X; Zhu J; Liu K
    Mediators Inflamm; 2018; 2018():4286364. PubMed ID: 29853789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
    Kuwahara M; Suzuki S; Takada K; Kusunoki S
    J Neuroimmunol; 2011 Oct; 239(1-2):87-90. PubMed ID: 21914557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.